NRAS G12C

Clinical trials for NRAS G12C explained in plain language.

Never miss a new study

Get alerted when new NRAS G12C trials appear

Sign up with your email to follow new studies for NRAS G12C, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

New immunotherapy targets tough cancers in early trial

Disease control Ongoing

This study tests an experimental immunotherapy called ELI-002 7P in people with pancreatic or other solid tumors that have certain KRAS or NRAS gene mutations. The treatment aims to help the immune system fight cancer cells. The trial involves about 158 participants and is in ear…

Matched conditions: NRAS G12C

Phase: PHASE1, PHASE2 • Sponsor: Elicio Therapeutics • Aim: Disease control

Last updated Apr 29, 2026 04:29 UTC

NRAS G12C

Get alerted when new NRAS G12C trials appear

New immunotherapy targets tough cancers in early trial